Filetype PDF | Posted on 06 Jan 2023 | 4 years ago
Authentication
digital resources
254x Filetype PDF File size 0.90 MB Source: www.gco-cancer.org
Les GCO à l’ESMO 2017
Les Groupes Coopérateurs en Oncologie (GCO) seront présents au congrès de l’ESMO (European
Society for Medical Oncology), qui se tiendra du 8 au 12 septembre à Madrid.
L’ESMO est le principal rendez-vous de la cancérologie au niveau européen au cours duquel sont
partagés les résultats d’études cliniques sur le traitement des cancers. Les GCO présenteront leurs
dernières études menées dans les cancers gynécologiques, digestifs, bronchiques ainsi que les
cancers de la tête et du cou.
5 communications orales, 7 posters discussion et 8 posters portant
sur des essais promus ou réalisés en collaboration avec l’un des
membres des GCO.
CANCERS DE LA TETE ET DU COU ......................................................................................................... p.2
CANCERS DIGESTIFS (COLORECTAUX ET NON COLORECTAUX) ........................................................... p.2
CANCERS GYNECOLOGIQUES ............................................................................................................... p.3
CANCERS DU POUMON ........................................................................................................................ p.4
1
Lettre d’information des GCO – 7 septembre 2017
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
CANCERS DE LA TETE ET DU COU
GORTEC : Groupe Oncologie Radiothérapie Tête et Cou
Poster display session
Chemoradiotherapy versus radiotherapy in the treatment of salivary glands and nasal
tumors: the GORTEC 2016-02 study
Abstract
CANCERS DIGESTIFS (COLORECTAUX ET NON COLORECTAUX)
FFCD : Fédération Francophone de Cancérologie Digestive
GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie
Poster display session
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic
or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French
interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study)
Abstract
FFCD : Fédération Francophone de Cancérologie Digestive
Proffered paper (oral) session
Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-
risk stage II and III colon cancers: A phase II multicentre randomised controlled trial
(PRODIGE 22)
Abstract
Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-
based adjuvant chemotherapy
Abstract
Poster display session
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases
(RCSM): final results of the FFCD 1102 phase II trial.
Abstract
Predictive factors for early progression during induction chemotherapy (IC) and
chemotherapy-free interval (CFI). Analysis from PRODIGE 9 trial
Abstract
2
Lettre d’information des GCO – 7 septembre 2017
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
PRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo
in resected stage III or high risk stage II colon cancer with PIK3CA mutation
Abstract
PRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without
DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-
gastric adenocarcinoma
Abstract
CANCERS GYNECOLOGIQUES
ARCAGY - Association de Recherche sur les CAncers dont GYnécologiques
GINECO - Groupe d’Investigateurs Nationaux pour l’Étude des Cancers Ovariens et du sein
Proffered paper (oral) session
Quality of Life in Patients with Recurrent Ovarian Cancer (OC) Treated with Niraparib:
Results from the ENGOT-OV16/NOVA Trial
Abstract
Poster discussion session :
Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed
ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)
Abstract
The Exposure-Response Relationship of Niraparib in Patients with gBRCAmut and Non-
gBRCAmut: Results from the ENGOT-OV16/NOVA Trial
Abstract
Safety and Efficacy of Niraparib in Elderly Patients (Pts) with Recurrent Ovarian Cancer (OC)
Abstract
BRCA1&2 tumoral and germline status for ovarian cancer patients in first line setting within
the PAOLA-01 trial
Abstract
Long term quality of life among epithelial ovarian cancer patients: The GINECO case/control
VIVROVAIRE Study
Abstract
3
Lettre d’information des GCO – 7 septembre 2017
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
Poster display session
Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in
recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study
Abstract
A GINECO phase II study of Navitoclax (ABT 263) in women with platinum
resistant/refractory recurrent ovarian cancer (ROC)
Abstract
CANCERS DU POUMON
IFCT : Intergroupe Francophone en Cancérologie Thoracique
Presidential symposium
Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan based follow-up for
completely resected non-small cell lung cancer (NSCLC).
Abstract
Proffered paper (oral) session
Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural
Mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase 2 trial.
Abstract (under embargo until 10.09.17)
Poster discussion session
IFCT‐1502 CLINIVO: Real‐life experience with nivolumab in 600 patients (pts) with advanced
Non‐Small Cell Lung Cancer (NSCLC): efficacy and safety of nivolumab and post‐nivolumab
treatment in the French Expanded Access Program (EAP)
Abstract
Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve
non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide
program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT).
Abstract
Retrouvez tous les abstracts sur le site de l’ESMO :
http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts
4
Lettre d’information des GCO – 7 septembre 2017
GCO/IFCT
10 rue de la Grange-Batelière - 75009 Paris
Tel: +33 1.80.96.08.03 http://www.gco-cancer.org/
no reviews yet
Please Login to review.
